Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HTR5A | P47898 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22704957 | 0.91 | ADORA3 (0.58) | ADORA3TK1HPGDHRH2HTR5A | |
| SCHEMBL12269824 | 0.81 | ADORA3 (0.66) | ADORA3HSP90AA1HSP90B1HTR2CHTR2B | |
| SCHEMBL26534073 | 0.81 | ADORA3 (1.00) | ADORA3HSP90AA1HSP90B1HTR2CHTR2B | |
| SCHEMBL12269794 | 0.79 | HTR2B (0.55) | ADORA3HSP90AA1HSP90B1HTR2CHTR2B | |
| SCHEMBL19415065 | 0.79 | HTR2B (0.55) | ADORA3HSP90AA1HSP90B1HTR2CHTR2B | |
| SCHEMBL29573575 | 0.79 | HTR2B (0.47) | ADORA3HSP90AA1HSP90B1HTR2CHTR2B | |
| SCHEMBL22236552 | 0.78 | ADORA3 (0.47) | ADORA3TK1HPGDSTING1PDE3B | |
| SCHEMBL15588481 | 0.78 | ADORA3 (0.47) | ADORA3TK1HPGDSTING1PDE3B | |
| SCHEMBL12269843 | 0.74 | ADORA3 (0.59) | ADORA3HSP90AA1HSP90B1HTR2CHTR2B | |
| SCHEMBL19938129 | 0.74 | PI4KA (0.64) | HPGDSTING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | ADORA3 378/4885HSP90AA1 2538/4885HSP90B1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.